Errata & Revisions to the Mental health care guide for licensed practitioners and mental health professionals: Schizophrenia

- 1. On 4/19/2019, the following changes were made:
 - a. PAGE 9, SECTION 2, MEDICATION TABLES AND RESOURCES, MEDICATION TABLE NUMBER 1:
 - i. Correcting Aristada information to read:

Aripiprazole Lauroxil (Aristada)	LAI	54-57 days (Aristada) 15-18 days (Aristada Initio)	Adult only – establish tolerability in aripiprazole-naïve patients with minimum 14 day oral trial up to 30mg QD. Aristada Initio 675mg IM (deltoid or gluteal) plus a single dose of 30mg aripiprazole oral in conjunction with first dose of Aristada 441, 662, 882, or 1064mg IM. The first dose of Aristada may be administered same day as Aristada Initio or up to 10 days thereafter	For 10mg po daily dosage – use 441mg IM Q month For 15mg po daily dosage – use 662mg IM monthly or 882mg IM Q 6 weeks, or 1064mg IM Q 2 months. For 20mg oral dosage or greater – 882mg Q month		pplementation After Missed ne Since Last Aristada(R) I more than 6 to 7 weeks more than 8 to 12 weeks more than 8 to 12 weeks more than 10 to 12 weeks	more than 7 weeks more than 12 weeks more than 12 weeks	Ini ari fir Do ea	If not administering Aristada Initio, give concomitant oral aripiprazole for 21 days with first Aristada IM injection. Do not administer Aristada earlier than 14 days following the previous injection.		
					of Aristada Initio(TM) or	Administer a single dose of Aristada Initio(TM) or 7 days of oral aripiprazole	Administer a single dose of Aristada Initio(TM) plus a single dose of oral aripiprazole 30 mg or		Concomitant Medication	Aripiprazole Lauroxil Aristada(R) Dose Adjustment	
						21 days of oral aripiprazole at the same dose as when Aristada(R) was		CYP3A4 inducer	Increase 441 mg dose to 662 mg. No adjustment required for 662 mg, 882 mg, or 1064 mg doses.		
									Strong CYP3A4 inhibitor	Reduce to next lower strength (882 mg every 6 weeks or 1064 mg every 2 months is reduced to 441 mg monthly). May continue 441 mg dose, if tolerated.	
									Strong CYP3A4 inhibitor in poor	Reduce dose to 441 mg. May continue 441 mg	

	7			
		r	CYP2D6 metabolizer	dose, if tolerated.
			Strong CYP2D6 inhibitor	Reduce to next lower strength (882 mg every 6 weeks or 1064 mg every 2 months is reduced to 441 mg monthly). May continue 441 mg dose, if tolerated
		i i	Strong CYP2D6 inhibitor in poor CYP2D6 metabolizer	No adjustment required.
		ii s	Both strong CYP2D6 inhibitor and strong CYP3A4 inhibitor	Avoid concomitant use with 662 mg, 882 mg, or 1064 mg doses. May continue 441 mg dose, if tolerated.